



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/527,028	03/16/2000	Sylvie Veriac	0198/053	1839

7590                    10/02/2003

Elzbieta Chlopecka  
Pollock Vande Sande & Amernick LLP  
P O Box 19088  
Washington, DC 20036-3425

EXAMINER

GABEL, GAILENE

ART UNIT

PAPER NUMBER

1641

DATE MAILED: 10/02/2003

15

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application N .</b>	<b>Applicant(s)</b>	
	09/527,028	VERIAC ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Gailene R. Gabel	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 05 May 2003.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 12 and 14-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 12 and 14-24 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                             | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)         | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____                                    |

**DETAILED ACTION**

***Amendment Entry***

1. Applicant's amendment and response filed 5/5/03 in Paper No. 13 is acknowledged and has been entered. Claim 12 has been amended. Claim 25 has been cancelled. Accordingly, claims 12 and 14-24 are pending and are under examination.

**Rejections Withdrawn**

***Claim Rejections - 35 USC § 112/103***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. The rejections of claim 25 are now moot in light of Applicant's cancellation of the claim.
3. In light of Applicant's amendment, the rejection of claims 12 and 14-24 under 35 U.S.C. 112, second paragraph, is hereby, withdrawn.
4. In light of Applicant's amendment, the rejection of claims 12 and 14-24 under 35 U.S.C. 103(a) as being unpatentable over Sakata et al. (US 5,538,893) in view of Hamaguchi et al. (US 5,389,549) and in further view of Uchihashi et al. (US 5,968,832) is hereby, withdrawn.

**New Grounds of Rejection**

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 12 and 14-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sakata et al. (US 5,538,893) in view of Hamaguchi et al. (US 5,389,549).

Sakata et al. disclose a single reagent for analyzing and classifying leucocytes including basophil, which is capable of determining cell size and morphological features of all leucocytes (see Abstract and column 6, lines 60-64). Specifically, the single reagent comprises a buffer for adjusting the pH to 2.5 - 4.0, a cationic detergent (surfactant), and also an inorganic salt. The cationic detergent includes quaternary ammonium salts for complete lysis of erythrocytes and baring the nuclei of granulocytes

other than basophil (see column 4, lines 21-59). The cationic detergent is preferred at a concentration of 1 g/l to 10 g/l (see column 4, lines 53-64). The reagent buffer used includes citric acid and tartaric acid in addition to alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, for adjusting pH to a desired pH of 2.0 - 5.0 (see column 5, lines 25-40). The inorganic salts include alkali metal salts such as sodium chloride and potassium chloride (see column 6, lines 1-6). According to Sakata et al., the surfactants, the buffer, and the salts are prepared and mixed at desired ratios (see column 5, lines 44-63). Sakata et al. disclose that at appropriate concentrations, cell lysing is exhibited and lymphocytes and monocytes, immature granulocytes and basophils which include a large percentage of basophilic granules are hardly shrunk allowing differentiation in sizes of leucocytes (see column 7, lines 36-47).

Sakata et al. differ in failing to disclose the single reagent as further comprising nitrogenous compound.

Hamaguchi et al. disclose a hematologic reagent for counting and classifying leucocytes including basophil and lysing erythrocytes. Specifically, the reagent comprises a blood diluent including a phosphate buffer which maintains the pH at 1.5 - 5.0, sodium chloride, a nonionic detergent; and a nitrogenous compound for use in reducing the size of monocytes in leucocytes. Hamaguchi et al. disclose that nitrogenous compounds are solubilizing agents which include thiourea or 1,3-dimethylurea. Specifically, Hamaguchi et al. disclose that when incorporated into a reagent, the solubilizing agent selectively promotes the action of the lysing reagent into monocytes. Such selective action of solubilizing agents to monocytes is also effective

with other reagents used in leucocyte classification. Hamaguchi et al. further disclose that the reagent comprising a buffer having potassium phthalate, hydrochloric acid, nitric acid, and a lysing agent at an acidic pH of 3.0, is enabled for basophil measurement.

It would have been obvious to one of ordinary skill in the art at the time of the instant invention to incorporate the solubilizing agent / nitrogenous compound as taught by Hamaguchi into the single reagent as taught by Sakata because Hamaguchi specifically suggested conventional applicability of nitrogenous compounds with hematologic reagents used in leucocyte classification such as the reagent taught by Sakata.

In as far as the recitation of intended use, i.e. single reagent ... for use in measurement of hemoglobin", the claimed single reagent "comprising a buffer, at least one cationic detergent, and nitrogenous compound", must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963). In this case, the combination of Sakata with Hamaguchi which suggests a "single reagent ... comprising a buffer, at least one cationic detergent, and nitrogenous compound", renders obvious the claimed invention.

Sakata et al. and Hamaguchi et al. differ from the instant invention in failing to disclose the specific concentration parameters of elements recited in claims 23 and 24.

It is, however, maintained that the concentration parameters such as detergent [0.2-20 g/l] and nitrogenous compound [0.1-10 g/l] recited in claim 23 and potassium chloride [5-15 g/l], 1,3- dimethyl-2- thiourea [0.5-5 g/l], dodecyltrimethylammonium chloride [0.5-5 g/l], and potassium hydrogen phosphate / HCl [1.0-10 g/l] which are recited in claim 24, are all result effective variables which the prior art references have shown may be altered in order to achieve optimum results. It has long been settled to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of a result effective variable. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation." Application of Aller, 220 F.2d 454, 456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). "No invention is involved in discovering optimum ranges of a process by routine experimentation." Id. at 458, 105 USPQ at 236-237. The "discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art." Application of Boesch, 617 F.2d 272, 276, 205 USPQ 215, 218-219 (C.C.P.A. 1980). Since Applicant has not disclosed that the specific limitations recited in instant claims 23 and 24 are for any particular purpose or solve any stated problem and the prior art teaches that the different reagent elements and parameters often vary according to the reagent system used or sample being analyzed and parameters appear to work equally as well; absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum workable ranges of the methods disclosed by the Sakata and Hamaguchi by normal optimization procedures known in the leucocyte differentiation art.

***Response to Arguments***

6. Applicant's arguments filed 5/5/03 have been fully considered but they are not persuasive.

A) Applicant argues that Hamaguchi et al. fail to teach nitrogenous compound such as thiourea.

Contrary to Applicant's argument, Hamaguchi et al., indeed, teach a nitrogenous compound such as thiourea or 1,3-dimethylurea incorporated into a single hematologic reagent (see column 8, lines 21-34).

B) Applicant argues that Hamaguchi et al. teaches away from the claimed invention which teaches a single reagent because Hamaguchi teaches a dual reagent.

In response, Hamaguchi et al. teach that any of the reagents disclosed may include or contain a nitrogenous compound; thus, Hamaguchi was combined with the teaching of Sakata for the generic use or inclusion of a nitrogenous compound with any hematologic reagent. Additionally, "comprising language" in claim 12 does not exclude the reagent disclosed by Hamaguchi.

C) Applicant argues that Sakata teaches away from the claimed invention because Sakata requires the pH to be in the range of 2.5 to 4.0.

In response, the claimed invention does not exclude the range of pH as taught and required by Sakata et al.

D) Applicant argues that Hamaguchi teaches away from the claimed invention in disclosing inoperability; thus, exclusion of quaternary ammonium salts, in his reagent.

In response to applicant's argument that the teaching of quaternary ammonium salts in the teaching of Sakata renders the combination between the Sakata reference and Hamaguchi reference inoperable, the test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981). In this case, Sakata discloses a single reagent which comprises a buffer for adjusting the pH to 2.5 - 4.0, a cationic detergent, and also an inorganic salt. The cationic detergent includes quaternary ammonium salts. Hamaguchi is incorporated for his disclosure of a hematologic reagent including a phosphate buffer which maintains the pH at 1.5 - 5.0, sodium chloride, an nonionic detergent, and having incorporated thereto, a nitrogenous compound, i.e. thiourea or 1,3- dimethylurea. According to Hamaguchi, the selective action of solubilizing agents to monocytes is also effective for use with other reagents capable of leucocyte classification; thus, suggesting applicability of nitrogenous compounds with other reagents such as taught by Sakata.

7. No claims are allowed.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R. Gabel whose telephone number is (703) 305-0807. The examiner can normally be reached on Monday, Tuesday, and Thursday, 5:30 AM to 2:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703) 305-3399. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-0169.

Gailene R. Gabel  
Patent Examiner  
Art Unit 1641  
September 30, 2003 *gj*

*Christopher L. Chin*

CHRISTOPHER L. CHIN  
PRIMARY EXAMINER  
GROUP 1800/641